Original Research
Published on 18 Mar 2025
A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas
in Cancer Immunity and Immunotherapy
- 3,281 views
- 1 citation
Original Research
Published on 18 Mar 2025
in Cancer Immunity and Immunotherapy
Methods
Published on 25 Jan 2016
in Radiation Oncology
Original Research
Published on 07 Dec 2015
in Radiation Oncology
Original Research
Published on 24 Apr 2020
in Pharmacology of Ion Channels and Channelopathies
Original Research
Published on 06 Jul 2023
in Breast Cancer
Original Research
Published on 08 Dec 2021
in Radiation Oncology
Original Research
Published on 22 Nov 2018
in Radiation Oncology
Original Research
Published on 07 Aug 2020
in Radiation Oncology
Original Research
Published on 30 Jan 2025
in Neuro-Oncology and Neurosurgical Oncology
Original Research
Published on 17 Mar 2021
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 13 Mar 2017
in Radiation Oncology
Original Research
Published on 17 Feb 2014
in Radiation Oncology
Original Research
Published on 01 Mar 2022
in Head and Neck Cancer
Original Research
Published on 19 May 2014
in Molecular and Cellular Oncology
Original Research
Published on 09 Dec 2024
in Non-Neuronal Cells
Original Research
Published on 11 Feb 2020
in Cancer Endocrinology